European regulators have cleared Fractyl Health to begin a clinical study of a GLP-1 gene therapy candidate. The decision adds momentum to efforts to replace chronic GLP-1 injections and pills with a single treatment intended to deliver longer-lasting incretin signaling. The move is notable for biotech drug developers because GLP-1 biology is already a major commercial battleground, and gene therapy entrants are now competing on both durability and safety profiles.